Welcome to our dedicated page for THERIVA BIOLOGICS news (Ticker: TOVX), a resource for investors and traders seeking the latest updates and insights on THERIVA BIOLOGICS stock.
Theriva Biologics, Inc. develops therapeutics for cancer and related diseases as a diversified clinical-stage biotechnology company. Its subsidiary, Theriva Biologics, S.L., is developing an oncolytic adenovirus platform for intravenous, intravitreal and antitumoral delivery. The company’s lead candidate, VCN-01, is designed to replicate selectively within tumor cells and degrade the tumor stroma barrier associated with cancer treatment resistance.
Recurring Theriva Biologics news includes VCN-01 clinical data in metastatic pancreatic ductal adenocarcinoma and retinoblastoma, regulatory interactions with U.S. and European agencies, medical-conference presentations, and operational financial results. Coverage also includes SYN-004, or ribaxamase, for gastrointestinal degradation of certain IV beta-lactam antibiotics, and the licensed SYN-020 recombinant intestinal alkaline phosphatase program.
Theriva Biologics (NYSE American: TOVX) entered a warrant inducement agreement to accelerate the exercise of existing warrants for up to 7,360,460 shares at a reduced price of $0.54 per share, generating approximately $4.0 million in gross proceeds, with an offer window to raise up to an additional $0.4 million. In return, investors will receive new unregistered warrants to purchase up to 14,720,920 shares at $0.54, exercisable after stockholder approval and expiring five years after the Approval Date. Closing is expected on or about October 17, 2025. Net proceeds are intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners acted as exclusive financial advisor.
Theriva Biologics (NYSE American: TOVX) announced two upcoming medical meeting presentations on October 20, 2025. VCN-01 expanded data from the VIRAGE Phase 2b trial in metastatic pancreatic cancer (mPDAC) will be presented as a mini-oral at ESMO 2025 by Dr. Rocío Garcia-Carbonero (Abstract #2216MO) at 09:28 a.m. CEST in Bonn Auditorium, Messe Berlin.
SYN-004 blinded safety and PK data from the Phase 1b/2a randomized, double-blinded, placebo-controlled trial in allogeneic HCT recipients will be presented as a poster at IDWeek 2025 by Dr. Erik R. Dubberke (Abstract #P-104) on October 20, 2025 from 12:15–1:30 p.m. EDT in Poster Hall B4-5, Georgia World Congress Center, Atlanta.
Theriva Biologics (NYSE American: TOVX) will present preclinical data for VCN-12, a next‑generation oncolytic adenovirus from the VCN‑X discovery program, at the 32nd Annual ESGCT meeting in Seville on Oct 8, 2025 at 08:30 CEST.
Presenter Dr. Ramón Alemany will describe mechanistic data showing VCN‑12 is derived from clinical lead VCN‑01 and is armed with additional transgenes intended to improve tumor cell lysis, stroma degradation, and antitumor immunity. A pre‑ESGCT monograph also reports preclinical intracranial administration data for VCN‑01 supporting further development for brain tumors.
Theriva Biologics (NYSE American: TOVX) reported significant progress in Q2 2025, highlighted by positive topline results from their VIRAGE Phase 2b trial of VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic cancer. The drug, combined with standard chemotherapy, demonstrated improved overall survival, progression-free survival, and duration of response.
The company also presented Phase 1 safety and clinical outcome data for VCN-01 in retinoblastoma at ASCO 2025. Financially, Theriva reported $12.1 million in cash as of June 30, 2025, with runway extending into Q1 2026. General and administrative expenses increased significantly to $11.2 million, while R&D expenses decreased 34% to $2.0 million.
Theriva Biologics (NYSE American: TOVX) has completed its previously announced public offering, raising $7.5 million in gross proceeds. The offering consisted of 6,818,180 shares of common stock (or pre-funded warrants) and warrants to purchase an equal number of shares at a combined price of $1.10 per share and accompanying warrant.
The warrants are immediately exercisable at $1.10 per share and will expire in five years. The company plans to use the proceeds for working capital, general corporate purposes, research and development, and manufacturing scale-up. A.G.P./Alliance Global Partners served as the sole placement agent for the offering.
Theriva Biologics (TOVX) has announced the pricing of a public offering to raise approximately $7.5 million through the sale of up to 6,818,180 shares of common stock (or pre-funded warrants) and warrants at a combined price of $1.10 per share. The accompanying warrants will have an exercise price of $1.10 per share, be immediately exercisable, and expire in five years.
The offering is expected to close around May 8, 2025. The company plans to use the proceeds for working capital, general corporate purposes, research and development, and manufacturing scale-up. A.G.P./Alliance Global Partners is serving as the sole placement agent for this offering.
- Progression-free survival improved to 7.0 months vs 4.6 months in control group
- Duration of response doubled to 11.2 months vs 5.4 months in control group
- Patients receiving 2 doses of VCN-01 showed even better results with 14.8 months overall survival
- Treatment was well-tolerated with manageable side effects
Theriva Biologics (NYSE American: TOVX) has announced the presentation of blinded safety and pharmacokinetic data from their ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase). The trial focuses on allogeneic hematopoietic cell transplant recipients for the prevention of acute graft-versus-host-disease (aGVHD).
The data will be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria, April 11-15, 2025. Dr. Erik R. Dubberke from Washington University School of Medicine will present the ePoster (E0145) titled 'Safety and tolerability of SYN-004 in allogeneic haematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T)' on April 12, 2025.